Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-704 vs Skyrizi in healthy adults
NCT07258745Phase 1Recruiting
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of risankizumab in psoriasis (3 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Observed Serum Concentration at 146 days and Area Under Concentration-Time Curve From Time 0 to Infinity at 146 days. Started Nov 2025; status: recruiting.
02
Drugs
risankizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT07258745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07258745.